Every story stays here. Filter by topic, search older headlines, and save favorites to your member record. Educational notes only — not medical advice.
King's College London researchers reported in FEBS Open Bio that KCL-286, an oral drug first made for spinal cord injury, reduced DNA double-strand breaks and inflammation in a mouse model of Alzheimer's disease. The drug activates a retinoic-acid receptor beta pathway. KCL-286 has already cleared a Phase 1 safety and tolerability study in people for that earlier program. That study did not test Alzheimer's disease. Jonathan Corcoran and Maria Goncalves described the mouse findings as early. Benefit against Alzheimer's in people is not known. This is not a treatment a person can ask to start, and it is not a substitute for prescribed care. DOI 10.1002/2211-5463.70284. ScienceDaily dated its page 2 November 2026. The feed time falls on 3 November in Bangkok. Not medical advice.
USC researchers reported in the Journal of Biological Chemistry that two weeks of cinaciguat, an experimental drug, restored pores in aging liver sinusoidal endothelial cells in older rats. Circulating amyloid-beta fell by about half, near the levels in young rats. LDL cholesterol also fell to youthful levels. The group describes a signal in which those lining cells release HB-EGF and neighboring hepatocytes take up more LDL and amyloid-beta. Laurie DeLeve said more translational work is required. The study did not show fewer brain plaques, and it did not count heart attacks. It is rat research, not a medicine for people, and not a substitute for prescribed care. DOI 10.1016/j.jbc.2026.113608. ScienceDaily dated its page 2 November 2026. The feed time falls on 3 November in Bangkok. Not medical advice.
A retrospective cohort published 3 November 2026 matched 104 people with non-arteritic central retinal artery occlusion, 52 who received papaverine hydrochloride and 52 who did not. Functional vision, defined as best-corrected acuity of 20/100 or better, was more common with the drug at discharge (32.7 percent versus 15.4 percent) and at one month (53.8 percent versus 34.6 percent). Adjusted odds ratios were 3.52 at discharge and 3.15 at one month. The pattern looked similar across age, sex, which eye was affected, and whether thrombolysis was also used. This is not a randomized trial. It cannot show that the medicine caused the difference. The authors said prospective studies are still needed. It is not a reason to start this drug. That decision is clinician-only. Not medical advice.
On 3 November 2026 Cell Metabolism published a letter from Cong Xie, Tongzhi Wu, and colleagues about a hepatocyte study from Ye and colleagues. The letter says liver-derived alkaline phosphatase can, in experimental fatty-liver models, hold intestinal stem cells back from becoming L-cells that release GLP-1 and peptide YY. The letter adds that a fasting GLP-1 level in people may not count those cells, and that the alkaline phosphatase relationship may differ by population. The study authors replied the same day that they agree a fasting GLP-1 level is not a stand-in for L-cell number or for incretin function. This is a letter exchange, not a new trial. GLP-1 receptor agonist drugs are prescribed medicines. They are not a substitute for that care, and this letter is not a reason to start, stop, or swap any medicine. Off-label use is clinician-only. Not medical advice. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
American Heart Association Scientific Sessions 2026 abstract MDP0323, not yet a peer-reviewed study, reviewed 28,345 FDA adverse-event reports from 2017 to 2025 in people ages 13 and older. Of those, 854 mentioned caffeine or a stimulant supplement, set against 27,491 reports about products without those ingredients. Cardiac arrest was reported about 11 times more often with the caffeine and stimulant products. Those reports were about 4.5 times more likely to include a heart attack and four times more likely to include ventricular arrhythmia or palpitations. Elevated heart rate was nearly 3 times more often, chest pain 2.71 times more often, and fainting about 2 times more often. About 45 percent of the cardiovascular reports tied to those products involved adults ages 18 to 34. Similar patterns were seen in reports about men and in reports about women. Sai Samayamanthula and Gregory Marcus both said this does not prove the products caused the events: the reports are voluntary, and the number of people who used the products without an event is unknown. Not medical advice.
Clalit Health Services records for 52,330 women in Israel, ages 45 to 59, with no history of heart disease, blood clots, or cancer, compared women who started contemporary prescription hormone therapy with matched women who saw a gynecologist and did not start it. Matching included age, body mass index, blood pressure, cholesterol, smoking, and socioeconomic status. Over an average of 12 years (records ran as long as 23 years), heart attack, stroke, or related heart disease occurred in 2,311 women on therapy (4.4 percent) and 2,383 women not on it (4.6 percent). Death before age 80 occurred in 659 (1.3 percent) versus 653 (1.2 percent). A blood clot occurred in 174 versus 175 women (0.33 percent in both). Results were similar for oral, patch, and gel forms. This is an observational comparison presented as American Heart Association Scientific Sessions 2026 abstract MDP0654. It is not peer-reviewed and cannot prove cause. Unmeasured differences remain. It is not a reason to start or stop prescription hormone therapy. That decision is clinician-only. Not medical advice, and not a substitute for heart care.
Soonhuae and colleagues report a pilot trial in Experimental Gerontology (November 2026; volume 225; article 113343; Epub 29 September 2026; DOI 10.1016/j.exger.2026.113343; PMID 42810600). Eight older adults with coronary artery disease, 6 men and 2 women, age 74 years (SD 8), body mass index 29.2 (SD 5.0), completed a randomized, double-blind, placebo-controlled crossover of a dietary nitrate supplement, taken as beetroot juice. For two weeks, twice a day, they took nitrate-rich beetroot juice or a nitrate-depleted beetroot placebo, then crossed over. Retention was 100 percent, adherence was 100 percent, and no adverse effects needed medical treatment. Flow-mediated dilation changed by +0.98 percentage points after the nitrate-rich juice (90 percent CI 0.17 to 1.80; Hedges g 0.72). The placebo mean change was -0.75 percent (90 percent CI -1.53 to 0.04). The nitrate-rich arm was 1.73 percentage points higher than placebo (90 percent CI 0.32 to 3.15; Hedges g 0.73). Arterial stiffness and hemodynamics barely moved. This is a pilot of eight people. It is not proof of a heart benefit a clinician should act on. Not medical advice, and not a substitute for clinician-directed heart care. Both sexes were included, so the gender tag is all, not men.
Ben Mhamed and colleagues, including Knechtle, report in the European Journal of Sport Science (November 2026; e70279; DOI 10.1002/ejsc.70279; PMID 42929456). PubMed indexed the record on 26 October 2026. The card date is 1 November 2026, the issue month. Fifty-nine male athletes (power n = 30, endurance n = 29) took 30 grams a day of whey, or a placebo, for 8 weeks, in a randomized, double-blind, placebo-controlled design. The athletes were already in training. The paper reports reductions in ALT, AST, and creatine kinase after whey supplementation, with p-values 0.001, 0.015, 0.001, and 0.003 printed for those reductions. It does not map each p-value onto one marker in a single sentence, so this card does not assign them. Only ALT had a significant time by supplementation by training-modality interaction (p = 0.003). CRP, an inflammatory marker, was measured. A within-group CRP drop in the supplemented power group (p = 0.039) was not backed by a significant three-way interaction, so it is not evidence the two training types responded differently. Placebo groups were stable or rose, particularly in the endurance group. This was added protein intake in athletes who were training. It is not a liver-disease treatment and not medical advice. Age was not stated, so the age tag is all ages.
ScienceDaily posted this on 31 October 2026. Robert J. Johnston Jr. and colleagues at Johns Hopkins report in PNAS (Hussey et al., DOI 10.1073/pnas.2510799123) that retinoic acid, a signal made from vitamin A, helps decide which cone cells form in the center of human retinal organoids grown from fetal tissue. The researchers say the foveola accounts for about half of visual perception. In the organoids, some blue cones were present around weeks 10 to 12, and by week 14 those cells appeared to have converted toward red and green cones. Retinoic acid limited blue cones in the center, and thyroid hormone helped leftover blue cones become red or green. That challenges a model, about 30 years old, in which blue cones migrate inward and their identities stay fixed. The work does not fully rule migration out. Hussey is now at CiRC Biosciences. This is lab-grown fetal tissue. It is not a trial of vitamin A pills, and it does not show that an adult vitamin A supplement improves sharp vision. Cell replacement is a long-term research hope, not a treatment from this result. Not medical advice.
Medical Xpress posted this on 29 October 2026. These are preliminary findings presented by Alessandra Carvalho Goulart of the University of São Paulo Faculty of Medicine at FAPESP Week Netherlands. This is a conference briefing. The English sources used here do not give a journal DOI. Contemporaneous accounts of the same talk describe the EMMA cohort, which is FAPESP-funded: 769 people with acute stroke seen from 2006 to 2018, of whom 65.5 percent were 65 or older and 54.2 percent were women. A heat wave was at least two consecutive days with a maximum of at least 33.1 degrees Celsius (92 degrees Fahrenheit). In a heat-only model, the odds ratio was 1.121 per additional heat-wave day. A continuous interaction of heat with PM10 had an odds ratio of 1.404, described as 40.4 percent higher odds per additional day of that combination. Those counts and odds ratios are attributed to accounts of that same preliminary talk. This card does not add a dehydration or blood-thickness explanation, because that wording was not in the primary account used here. The series includes both women and men, so it is not tagged as a women-only result. It is specific to São Paulo patients with stroke. It does not show that one hot day causes a stroke in an individual. Not medical advice.
News-Medical posted this on 29 October 2026. The American Geriatrics Society Healthy Aging Special Interest Group published a clinician framework in the Journal of the American Geriatrics Society (DOI 10.1111/jgs.70769). The society's own note is on its media-center page for the same framework. The card links to the News-Medical report. This is not a trial. The paper uses cases to apply the Geriatrics 5Ms, Mind, Mobility, Medications, Multicomplexity, and What Matters Most, to incretin therapy, including GLP-1 medicines. Older adults were under-represented in the drug trials the framework is responding to. The authors tell clinicians to weigh sarcopenia, frailty, loss of lean mass, malnutrition, and dehydration, to check function, nutrition, and cognitive impairment before treatment, and to pair therapy with resistance training and adequate protein. Team care may include a dietitian, a physical therapist, a trainer, and behavioral health. Language in the society material that these drugs look promising for weight and glycemic control is the society's framing, not a VitaLonga recommendation. Sex was not a result in this framework. Prescribing is clinician-only. Not medical advice. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Medical Xpress posted this on 28 October 2026. Vishwa Deep Dixit, Chenyang Guan, and colleagues at Yale report in Cell (DOI 10.1016/j.cell.2026.09.061) that taurine in human serum was higher at ages 60 to 99 than at ages 20 to 40, the opposite of a simple decline-with-aging guess. This was not a pill trial. In cultured macrophages, the cells released up to 80 percent of their taurine as the NLRP3 danger sensor assembled after signals that included bacterial toxins. Putting taurine back stopped the downstream NLRP3 responses the team measured. Lowering taurine sped NLRP3 inflammation even in young mice. Dixit called the result a first step in how that sensor is switched on, and said translation to older adults is still being studied. A separate calorie-restriction program, CALERIE, has reported that taurine rose during restriction. That is background, not this experiment. Sex was not stated for the serum comparison. The stated human age bands are 20 to 40 and 60 to 99, so this card is not tagged to the 40 to 59 band. The result is not a reason to start a taurine supplement. Not medical advice.
VitaLonga is an educational longevity resource, not a pharmacy, clinic, or doctor. Content is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease (DSHEA). Supplements can interact with medications and are not appropriate in every pregnancy or health condition. Consult a licensed clinician, especially if you take medications, are pregnant or nursing, or have a diagnosed condition.
